HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sustained improvement of clinical status and pulmonary hypertension in patients with severe heart failure treated with sildenafil.

AbstractBACKGROUND:
Sildenafil, a phosphodiesterase-5 inhibitor, has been shown to decrease pulmonary vascular resistance (PVR) in patients with heart failure. The purpose of the study was to evaluate the effect of sildenafil on clinical status and pulmonary vascular reactivity in patients with congestive heart failure.
MATERIAL AND METHODS:
We enrolled 20 patients (18 men and 2 women, mean age 51 ± 12 years, diagnosed with congestive heart failure and pulmonary hypertension. This was a prospective, single-center study. Patients were treated with sildenafil 25 mg TDS for 12 months. Protocol included NYHA evaluation and repeated echocardiography, cardiac pulmonary stress tests, and right- sided catheterization.
RESULTS:
Initially, there were 16 (80%) patients in III NYHA status and 4 (20%) patients in II NYHA. After 12 months, 8 patients were in NYHA III (40%) status and 12 patients in NYHA II (60%). Peak oxygen consumption increased from 12 ± 3 ml/kg/min to 19 ± 4 ml/kg/min after 1-year therapy (p<0.001). The cardiac index increased from 3.1 ± 0.6 L/min/m2 to 3.6 ± 0.4 L/min/m2 (p<0.05). Pulmonary vasculature resistance decreased after 1-year therapy (4.7 ± 1 vs. 1.6 ± 0.5 Woods units (p<0.005) comparing to initials. Mean pulmonary artery pressure decreased to 23 ± 6 mmHg from 42 ± 5 mmHg (p<0.001) after 1-year therapy.
CONCLUSIONS:
One-year sildenafil therapy effectively improved clinical status and pulmonary vascular resistance in patients diagnosed with congestive heart failure.
AuthorsTomasz Urbanowicz, Ewa Straburzyńska-Migaj, Izabela Katyńska, Aleksander Araszkiewicz, Zofia Oko-Sarnowska, Stefan Grajek, Marek Jemielity
JournalAnnals of transplantation (Ann Transplant) Vol. 19 Pg. 325-30 (Jul 09 2014) ISSN: 2329-0358 [Electronic] United States
PMID25007352 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Piperazines
  • Purines
  • Sulfones
  • Vasodilator Agents
  • Sildenafil Citrate
Topics
  • Adult
  • Cardiac Catheterization
  • Exercise Test (drug effects)
  • Female
  • Follow-Up Studies
  • Heart Failure (drug therapy)
  • Humans
  • Hypertension, Pulmonary (drug therapy)
  • Male
  • Middle Aged
  • Piperazines (administration & dosage)
  • Prognosis
  • Prospective Studies
  • Pulmonary Wedge Pressure (drug effects)
  • Purines (administration & dosage)
  • Severity of Illness Index
  • Sildenafil Citrate
  • Sulfones (administration & dosage)
  • Treatment Outcome
  • Vascular Resistance (drug effects)
  • Vasodilator Agents (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: